Jury orders Gilead's Kite Pharma to pay $752M for CAR-T patent infringement

courthouse
A California jury has ordered Gilead's Kite Pharma to pay $752 million for patent infringement. (Pixabay)

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

After a two-week trial, jurors in California ordered Gilead’s Kite Pharma to pay $752 million to BMS’ Juno Therapeutics and its partners, which sued in 2017 for patent infringement.

A BMS spokesperson said the company is "pleased" with the decision, while a Gilead representative said the company is "steadfast in our opinion" that the patent isn't infringed and is invalid. Gilead said it'll address its concerns in post-trial motions and through a potential appeal. 

In its lawsuit, Juno alleged Kite scientific collaborators copied research by scientists at Sloan Kettering to advance Kite’s CAR-T work and eventually win approval for CAR-T cancer med Yescarta. In 2013, Juno exclusively licensed a patent from Sloan Kettering and the Memorial Sloan Kettering Cancer Center covering the technology.  

RELATED: Kite Pharma, Juno duke it out in court over megamillion-dollar CAR-T patent 

In 2017, Kite scored a FDA approval for Yescarta; Juno contended the company was infringing the patent it licensed by marketing the med. 

Following a series of deals, Juno is now part of Bristol-Myers Squibb. Celgene first bought the CAR-T-focused biotech for $9 billion, and BMS just closed its massive Celgene merger. Kite Pharma joined Gilead under a 2017 buyout. 

Suggested Articles

GSK's Shingrix supply has recovered after COVID-19 prompted a slowdown in vaccinations.

Moderna will delegate fill-finish duties for "hundreds of millions" of doses of its COVID-19 vaccine to Spain's Laboratorios Farmacéuticos Rovi.

Their merger isn't official yet, but a new logo is ready to go: Mylan and Pfizer's Upjohn unit unveiled new branding for their Viatris combo Thursday.